Effects of Caffeic Acid, Rofecoxib, and Their Combination Against Quinolinic Acid-induced Behavioral Alterations and Disruption in Glutathione Redox Status

Overview

Journal Neurosci Bull

Specialty Neurology

Date 2009 Nov 21

PMID 19927170

Citations 12

Authors

Harikesh Kalonia

Puneet Kumar

Anil Kumar

Bimla Nehru

Affiliations

Soon will be listed here.

Abstract

Objective: The neuroprotective roles of cyclooxygenase (COX) and lipooxygenase (LOX) inhibitors have been well documented. Quinolinic acid (QA) is a well-known excitotoxic agent that could induce behavioral, morphological and biochemical alterations similar with symptoms of Huntington's disease (HD), by stimulating NMDA receptors. However, the exact roles of COX and LOX inhibitors in HD have not yet been explained. The present study aims to elucidate the effects of caffeic acid (a specific inhibitor for LOX), rofecoxib (a specific inhibitor for COX-2), and their combination in ameliorating QA-induced neurotoxicity in rats.

Methods: QA was injected into the right striatum of rats to induce neurotoxicity. Caffeic acid and rofecoxib were then orally administered separately. In the combination study, caffeic acid and rofecoxib were administered together. After that, a series of behavioral assessments were conducted to determine the effects of caffeic acid and rofecoxib, respectively, and the co-effect of caffeic acid and rofecoxib, against QA-induced neurotoxicity.

Results: Intrastriatal QA administration (300 nmol) not only induced a significant reduction in body weight and motor incoordination, but also altered the redox status (decreased glutathione and increased oxidized glutathione level) in striatum, as compared to the sham group. Moreover, chronic treatment with caffeic acid (5 mg/kg and 10 mg/kg, respectively, p.o.) or rofecoxib (10 mg/kg, p.o.) could significantly attenuate QA-induced behavioral alterations and restore the redox status in striatum. However, at the dose of 2.5 mg/kg, caffeic acid did not show any significant effects on these parameters in QA-treated rats. Furthermore, the combination of rofecoxib (10 mg/kg) and caffeic acid (5 mg/kg) could significantly protect against QA neurotoxicity.

Conclusion: The in vivo study indicates that excitotoxic injury to the brain might affect oxidant/antioxidant equilibrium by eliciting changes in glutathione. Moreover, the LOX and the COX pathways may be both involved in quinolinic-induced neurotoxicity, which provides a promising target for HD treatment.

Citing Articles

Pathomechanisms of behavioral abnormalities in Huntington disease: an update.

Jellinger K J Neural Transm (Vienna). 2024; 131(9):999-1012.

PMID: 38874766 DOI: 10.1007/s00702-024-02794-y.

An Overview of the Pathophysiological Mechanisms of 3-Nitropropionic Acid (3-NPA) as a Neurotoxin in a Huntington's Disease Model and Its Relevance to Drug Discovery and Development.

Upadhayay S, Yedke N, Rahi V, Singh S, Kumar S, Arora A Neurochem Res. 2023; 48(6):1631-1647.

PMID: 36738367 DOI: 10.1007/s11064-023-03868-1.

Therapeutic Implications of Caffeic Acid in Cancer and Neurological Diseases.

Alam M, Ahmed S, Elasbali A, Adnan M, Alam S, Hassan M Front Oncol. 2022; 12:860508.

PMID: 35359383 PMC: 8960963. DOI: 10.3389/fonc.2022.860508.

Neuroprotective Effects of Coffee Bioactive Compounds: A Review.

Socala K, Szopa A, Serefko A, Poleszak E, Wlaz P Int J Mol Sci. 2020; 22(1).

PMID: 33374338 PMC: 7795778. DOI: 10.3390/ijms22010107.

Anti-inflammatory activity of copao (Eulychnia acida Phil., Cactaceae) fruits.

Jimenez-Aspee F, Alberto M, Quispe C, Soriano M, Theoduloz C, Zampini I Plant Foods Hum Nutr. 2015; 70(2):135-40.

PMID: 25682221 DOI: 10.1007/s11130-015-0468-7.

References

Reed D, Fariss M . Glutathione depletion and susceptibility. Pharmacol Rev. 1984; 36(2 Suppl):25S-33S. View

Ellman G . Tissue sulfhydryl groups. Arch Biochem Biophys. 1959; 82(1):70-7. DOI: 10.1016/0003-9861(59)90090-6. View

Stanika R, Pivovarova N, Brantner C, Watts C, Winters C, Andrews S . Coupling diverse routes of calcium entry to mitochondrial dysfunction and glutamate excitotoxicity. Proc Natl Acad Sci U S A. 2009; 106(24):9854-9. PMC: 2701040. DOI: 10.1073/pnas.0903546106. View

Beal M . Neurochemistry and toxin models in Huntington's disease. Curr Opin Neurol. 1994; 7(6):542-7. DOI: 10.1097/00019052-199412000-00012. View

Choi D . Excitotoxic cell death. J Neurobiol. 1992; 23(9):1261-76. DOI: 10.1002/neu.480230915. View

Munday R, Winterbourn C . Reduced glutathione in combination with superoxide dismutase as an important biological antioxidant defence mechanism. Biochem Pharmacol. 1989; 38(24):4349-52. DOI: 10.1016/0006-2952(89)90641-2. View

Thiffault C, Aumont N, Quirion R, Poirier J . Effect of MPTP and L-deprenyl on antioxidant enzymes and lipid peroxidation levels in mouse brain. J Neurochem. 1995; 65(6):2725-33. DOI: 10.1046/j.1471-4159.1995.65062725.x. View

Szabo C . Multiple pathways of peroxynitrite cytotoxicity. Toxicol Lett. 2003; 140-141:105-12. DOI: 10.1016/s0378-4274(02)00507-6. View

Babu G, Bawari M . Single microinjection of L-glutamate induces oxidative stress in discrete regions of rat brain. Biochem Mol Biol Int. 1998; 43(6):1207-17. DOI: 10.1080/15216549700205041. View

10.

Tang T, Slow E, Lupu V, Stavrovskaya I, Sugimori M, Llinas R . Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proc Natl Acad Sci U S A. 2005; 102(7):2602-7. PMC: 548984. DOI: 10.1073/pnas.0409402102. View

11.

Reynolds Jr N, Lin W, Meyer Cameron C, Roerig D . Differential responses of extracellular GABA to intrastriatal perfusions of 3-nitropropionic acid and quinolinic acid in the rat. Brain Res. 1998; 778(1):140-9. DOI: 10.1016/s0006-8993(97)01048-2. View

12.

Gornall A, BARDAWILL C, DAVID M . Determination of serum proteins by means of the biuret reaction. J Biol Chem. 1949; 177(2):751-66. View

13.

Scattoni M, Valanzano A, Pezzola A, March Z, Fusco F, Popoli P . Adenosine A2A receptor blockade before striatal excitotoxic lesions prevents long term behavioural disturbances in the quinolinic rat model of Huntington's disease. Behav Brain Res. 2006; 176(2):216-21. DOI: 10.1016/j.bbr.2006.10.004. View

14.

Virag L, Szabo E, Gergely P, Szabo C . Peroxynitrite-induced cytotoxicity: mechanism and opportunities for intervention. Toxicol Lett. 2003; 140-141:113-24. DOI: 10.1016/s0378-4274(02)00508-8. View

15.

Sul D, Kim H, Lee D, Joo S, Hwang K, Park S . Protective effect of caffeic acid against beta-amyloid-induced neurotoxicity by the inhibition of calcium influx and tau phosphorylation. Life Sci. 2008; 84(9-10):257-62. DOI: 10.1016/j.lfs.2008.12.001. View

16.

Kukreja R, KONTOS H, Hess M, ELLIS E . PGH synthase and lipoxygenase generate superoxide in the presence of NADH or NADPH. Circ Res. 1986; 59(6):612-9. DOI: 10.1161/01.res.59.6.612. View

17.

Misko T, Highkin M, Veenhuizen A, Manning P, Stern M, Currie M . Characterization of the cytoprotective action of peroxynitrite decomposition catalysts. J Biol Chem. 1998; 273(25):15646-53. DOI: 10.1074/jbc.273.25.15646. View

18.

Beal M, Ferrante R, Swartz K, Kowall N . Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J Neurosci. 1991; 11(6):1649-59. PMC: 6575424. View

19.

Wise-Faberowski L, Pearlstein R, Warner D . NMDA-induced apoptosis in mixed neuronal/glial cortical cell cultures: the effects of isoflurane and dizocilpine. J Neurosurg Anesthesiol. 2006; 18(4):240-6. DOI: 10.1097/00008506-200610000-00004. View

20.

Manev H, Uz T, Sugaya K, Qu T . Putative role of neuronal 5-lipoxygenase in an aging brain. FASEB J. 2000; 14(10):1464-9. DOI: 10.1096/fj.14.10.1464. View